JOHNSON & JOHNSON COM (JNJ) : Transamerica Financial Advisors scooped up 26,552 additional shares in JOHNSON & JOHNSON COM during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 21, 2016. The investment management firm now holds a total of 68,412 shares of JOHNSON & JOHNSON COM which is valued at $7,752,448.JOHNSON & JOHNSON COM makes up approximately 0.65% of Transamerica Financial Advisors’s portfolio.
JOHNSON & JOHNSON COM closed down -0.14 points or -0.12% at $112.77 with 57,59,301 shares getting traded on Wednesday. Post opening the session at $112.96, the shares hit an intraday low of $112.46 and an intraday high of $113.2 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
Other Hedge Funds, Including , Albion Financial Group Ut boosted its stake in JNJ in the latest quarter, The investment management firm added 90 additional shares and now holds a total of 15,964 shares of JOHNSON & JOHNSON COM which is valued at $1,809,040. JOHNSON & JOHNSON COM makes up approx 0.30% of Albion Financial Group Ut’s portfolio.Windward Capital Management Co Ca reduced its stake in JNJ by selling 24,054 shares or 21.76% in the most recent quarter. The Hedge Fund company now holds 86,507 shares of JNJ which is valued at $9,802,973. JOHNSON & JOHNSON COM makes up approx 1.90% of Windward Capital Management Co Ca’s portfolio.Montrusco Bolton Investments reduced its stake in JNJ by selling 18,331 shares or 24.5% in the most recent quarter. The Hedge Fund company now holds 56,490 shares of JNJ which is valued at $6,401,447. JOHNSON & JOHNSON COM makes up approx 0.50% of Montrusco Bolton Investments’s portfolio.First United Bank Trust boosted its stake in JNJ in the latest quarter, The investment management firm added 436 additional shares and now holds a total of 19,716 shares of JOHNSON & JOHNSON COM which is valued at $2,172,309. JOHNSON & JOHNSON COM makes up approx 1.98% of First United Bank Trust’s portfolio.
On the company’s financial health, JOHNSON & JOHNSON COM reported $1.68 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Apr 19, 2016. Analyst had a consensus of $1.65. The company had revenue of $17482.00 million for the quarter, compared to analysts expectations of $17491.02 million. The company’s revenue was up .6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.56 EPS.
Many Wall Street Analysts have commented on JOHNSON & JOHNSON COM. Company shares were Reiterated by RBC Capital Mkts on Apr 20, 2016 to “Outperform”, Firm has raised the Price Target to $ 125 from a previous price target of $122 .Company shares were Reiterated by Piper Jaffray on Apr 20, 2016 to “Neutral”, Firm has raised the Price Target to $ 106 from a previous price target of $105 .Company shares were Reiterated by RBC Capital Mkts on Apr 15, 2016 to “Outperform”, Firm has raised the Price Target to $ 122 from a previous price target of $114 .
Johnson & Johnson is a holding company. The Company is engaged in the research and development manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Companys primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer Pharmaceutical and Medical Devices. The Company’s subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Companys research facilities are located in the United States Belgium Brazil Canada China France Germany India Israel Japan the Netherlands Singapore Switzerland and the United Kingdom.